IGF2BP1 could attenuate the tumor suppressive effect of cisplatin and induce cisplatin resistance in ovarian cancer, oral squamous cell carcinoma, seminoma, and endometrial cancer cells by regulating its target mRNA stabilization. The gene discussed is IGF2BP1; the disease is endometrial cancer.